[HTML][HTML] Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis
G Abbadessa, MT Lepore, S Bruzzaniti… - Neurology …, 2024 - AAN Enterprises
Background and Objectives The role of B cells in the pathogenic events leading to relapsing
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …
Effect of ocrelizumab on B-and T-cell receptor repertoire diversity in patients with relapsing multiple sclerosis from the randomized phase III OPERA Trial
Background and Objectives The B cell–depleting anti-CD20 antibody ocrelizumab (OCR)
effectively reduces MS disease activity and slows disability progression. Given the role of B …
effectively reduces MS disease activity and slows disability progression. Given the role of B …
[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
[HTML][HTML] Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
C Rodriguez-Mogeda, ZYGJ van Lierop… - Journal of …, 2023 - Springer
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
F van Puijfelik, KM Blok… - Brain …, 2024 - academic.oup.com
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary
progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however …
progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however …
Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology
CR Mancinelli, ND Rossi, R Capra - Therapeutics and Clinical …, 2021 - Taylor & Francis
The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …